Posters
« Back
Stem Cell Therapy For Diabetes
EP39017
Poster Title: Stem Cell Therapy For Diabetes
Submitted on 07 Jul 2022
Author(s): Sally Zou
Affiliations: Hunan Huateng Pharmaceutical Co. Ltd.
Poster Views: 110
View poster »


Poster Information
Abstract: In 1998, James Thomson, an American scientist, isolated embryonic stem cells from human blastocysts for the first time and successfully established a human embryonic stem cell line. Since then, it has become possible to obtain a variety of human functional cells in vitro, thus opening a new era of stem cell regenerative medicine.

In recent years, the development of stem cells in China is in full swing, and diabetes, as an important application direction of stem cells, has attracted great attention. A total of 208 diabetes-related stem cell therapy clinical trials are being conducted worldwide, including 42 registered projects in China, mainly involving the treatment of type 1 diabetes, type 2 diabetes, diabetic vasculopathy, neuropathy, diabetic foot and other complications.

stem cell therapy clinical trials.jpg

Strategies For Stem Cells To Treat Diabetes
At present, there are two main strategies for stem cell application in diabetes.

Transplantation of insulin-producing cells
The first strategy is to transplant insulin-producing cells. First, pluripotent stem cells (including embryonic stem cells and induced pluripotent stem cells) are directed to differentiate into insulin-producing cells with insulin-secreting function, which are then wrapped with an immune isolation device and transplanted into diabetic patients to reconstruct insulin-secreting function in diabetic patients.

In 2006, some scholars established a research strategy of "simulating pancreatic development in vivo/inducing pancreatic differentiation in vitro". For the first time, the differentiation of embryonic stem cells (ESCs) into insulin-producing cells was achieved through directional induction, and human ESC-derived islet-like β cells were obtained. When transplanted under the renal capsule of diabetic rats, it was found that the blood sugar of diabetic rats was significantly decreased, and the incidence of complications was significantly reduced. Studies have confirmed that the insulin-producing cells obtained from induced pluripotent stem cells (iPSCs) have reached the level of normal human pancreatic islets and have good clinical application prospects.

At present, some researchers have transplanted ESC-derived insulin-producing cells in the form of an immune isolation device and transplanted them into diabetic patients to conduct relevant clinical trials on fragile diabetic patients with extreme blood sugar fluctuations.

Direct transplantation of adult stem cells
Another important application strategy is the direct transplantation of adult stem cells. In 2016, a meta-analysis evaluated the effectiveness of various stem cell treatments for diabetes. The article included 22 stem cell-related studies. The analysis found that a considerable number of patients with type 1 diabetes could discontinue insulin after hematopoietic stem cell therapy, and 58% of them could discontinue insulin for more than 16 months.

The study also found that umbilical cord blood stem cells were ineffective for the treatment of type 1 or type 2 diabetes, and bone mesenchymal stem cells (BMSCs) showed inconsistent treatment effects for type 1 diabetes, and were partially effective for type 2 diabetes. This shows that the effect of stem cell therapy has a certain relationship with the source of stem cells.

Efficacy Analysis of Stem Cells In The Treatment of Diabetes
As far as some of the published clinical studies in China are concerned, there are great differences in the types of transplanted cells and selection criteria. Including but not limited to: autologous hematopoietic stem cell (HSC) transplantation for the treatment of type 1 diabetes, umbilical cord mesenchymal stem cells (UC-MSCs) for the treatment of type 1 diabetes, type 2 diabetes and diabetic foot, etc.

Among them, in the autologous hematopoietic stem cell transplantation for the treatment of type 1 diabetes, 12 of the 18 patients discontinued insulin after surgery, and the levels of fasting C-peptide and 2-hour postprandial C-peptide increased significantly after surgery and could be maintained for 1 year. The insulin use of the patients was reduced to varying degrees.

UC-MSCs also perform well in type 2 diabetes. After UC-MSCs infusion treatment, the fasting and postprandial blood glucose of the patients were significantly reduced, and the insulin resistance was significantly improved.

After angioplasty, patients with diabetic foot were given UC-MSCs infusion therapy. After 3 months, the skin temperature of the treatment group was increased, and the evaluation indicators such as ankle-brachial index, transcutaneous oxygen partial pressure, and claudication distance were significantly improved, the new blood vessels increased significantly, and the ulcers healed in whole or in part.
Summary: A total of 208 diabetes-related stem cell therapy clinical trials are being conducted worldwide, including 42 registered projects in China, mainly involving the treatment of type 1 diabetes, type 2 diabetes, diabetic vasculopathy, neuropathy, diabetic foot and other complications.References: [1]. Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis

[2]. Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic Rats
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons